BioSyent Declares Quarterly Dividend for 2024
BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) has announced a quarterly dividend of $0.045 per common share, which will be paid in Canadian Dollars. This dividend will be distributed to shareholders who are on record at the close of business shortly. This decision highlights the company’s ongoing dedication to providing value to its investors.
Details of the Quarterly Dividend
The declared dividend aligns with the payment made in the second quarter, reflecting BioSyent’s stable financial performance. This dividend is categorized as an 'eligible dividend' for Canadian income tax purposes, potentially making it more appealing to investors. The Board of Directors maintains the authority to adjust future dividends, allowing them to respond to evolving business conditions.
Schedule for Dividend Payment
The payment of the dividend is planned for a specific date, ensuring that shareholders receive their returns promptly. The company continues to showcase a robust dividend strategy, which emphasizes its strong economic foundation and profitable growth trajectory.
About BioSyent Inc.
BioSyent, traded on the TSX Venture Exchange under the symbol “RX”, is a profitable specialty pharmaceutical company focused on acquiring and developing innovative healthcare products. By concentrating on in-licensing successful pharmaceutical products, the company is committed to improving patient lives through effective medical solutions.
Growth and Strategic Focus
BioSyent has established itself as a growth-focused organization by marketing its products through various business units aimed at community, specialty, and international markets. This diversified strategy enables BioSyent to better support healthcare professionals and effectively address patient needs.
Current Shares and Financial Overview
The Company has a significant number of common shares outstanding, totaling 11,586,914, which reflects its active participation in the market. This level of transparency is part of BioSyent’s commitment to keeping its shareholders informed about its financial health.
Investor Relations
For those seeking real-time market quotes and additional financial insights about BioSyent, the company encourages investors to refer to relevant financial platforms. These resources are essential for keeping shareholders updated on the company’s market performance.
Contact Information
For direct inquiries or further assistance, investors can contact Mr. René C. Goehrum, President and CEO of BioSyent Inc. You can reach him via email at investors@biosyent.com or by phone at 905-206-0013. Additionally, BioSyent maintains an informative online presence through its corporate website.
Frequently Asked Questions
What is the declared dividend amount for Q3 2024?
The declared dividend for Q3 2024 is $0.045 per common share.
When is the dividend payment scheduled?
The payment is scheduled for a specific date, which will be confirmed based on the record date for shareholders.
What is the focus of BioSyent Inc.?
BioSyent focuses on in-licensing and acquiring innovative pharmaceutical and healthcare products.
How many common shares does BioSyent currently have outstanding?
BioSyent currently has 11,586,914 common shares outstanding.
Who can I contact for more information about BioSyent?
For more information, you can contact Mr. René C. Goehrum, the President and CEO, via email or phone.
